Bocciardi Renata, Bordo Domenico, Di Duca Marco, Di Rocco Maja, Ravazzolo Roberto
Laboratory of Molecular Genetics, G Gaslini Institute, Genova, Italy.
Eur J Hum Genet. 2009 Mar;17(3):311-8. doi: 10.1038/ejhg.2008.178. Epub 2008 Oct 1.
Fibrodysplasia ossificans progressiva (FOP, MIM 135100) is a rare genetic disorder characterized by congenital great toe malformations and progressive heterotopic ossification transforming skeletal muscles and connective tissues to bone following a well-defined anatomic pattern of progression. Recently, FOP has been associated with a specific mutation of ACVR1, the gene coding for a bone morphogenetic protein type I receptor. The identification of ACVR1 as the causative gene for FOP now allows the genetic screening of FOP patients to identify the frequency of the identified recurrent ACVR1 mutation and to investigate genetic variability that may be associated with this severely debilitating disease. We report the screening for mutations in the ACVR1 gene carried out in a cohort of 17 Italian patients. Fifteen of these displayed the previously described c.617G>A mutation, leading to the R206H substitution in the GS domain of the ACVR1 receptor. In two patients, we found a novel mutation c.774G>C, leading to the R258S substitution in the kinase domain of the ACVR1 receptor. In the three-dimensional model of protein structure, R258 maps in close proximity to the GS domain, a key regulator of ACVR1 activity, where R206 is located. The GS domain is known to bind the regulatory protein FKBP12 and to undergo multiple phosphorylation events that trigger a signaling cascade inside the cell. The novel amino-acid substitution is predicted to influence either the conformation/stability of the GS region or the binding affinity with FKBP12, resulting in a less stringent inhibitory control on the ACVR1 kinase activity.
进行性骨化性纤维发育不良(FOP,MIM 135100)是一种罕见的遗传性疾病,其特征为先天性大脚趾畸形以及进行性异位骨化,会按照明确的解剖学进展模式将骨骼肌和结缔组织转化为骨骼。最近,FOP与ACVR1的特定突变相关,ACVR1是一种编码I型骨形态发生蛋白受体的基因。ACVR1被确定为FOP的致病基因,这使得对FOP患者进行基因筛查成为可能,以确定已识别的复发性ACVR1突变的频率,并研究可能与这种严重致残疾病相关的基因变异性。我们报告了对一组17名意大利患者进行的ACVR1基因突变筛查情况。其中15名患者表现出先前描述的c.617G>A突变,导致ACVR1受体GS结构域中的R206H替换。在两名患者中,我们发现了一种新的突变c.774G>C,导致ACVR1受体激酶结构域中的R258S替换。在蛋白质结构的三维模型中,R258位于与GS结构域紧密相邻的位置,GS结构域是ACVR1活性的关键调节因子,R206也位于该区域。已知GS结构域可结合调节蛋白FKBP12,并经历多个磷酸化事件,从而触发细胞内的信号级联反应。预计这种新的氨基酸替换会影响GS区域的构象/稳定性或与FKBP12的结合亲和力,从而导致对ACVR1激酶活性的抑制控制不那么严格。